News

Filter

1 to 9 of 69 results

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

12-06-2014

US drug major Bristol-Myers Squibb has released new data from a Phase IIIb RA trial showing that the…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbOrenciaResearch

Bristol-Myers Squibb records $3.8 billion sales in first quarter

Bristol-Myers Squibb records $3.8 billion sales in first quarter

29-04-2014

US drug major Bristol-Myers Squibb has reported its first quarter results showing higher-than-expected…

AstraZenecaBaracludeBristol-Myers SquibbBusiness FinanceBusiness FinanceDapagliflozinFinancialOrenciaPharmaceuticalSprycelUnited StatesUSAYervoy

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Bristol-Myers Squibb releases strong third quarter results

Bristol-Myers Squibb releases strong third quarter results

23-10-2013

Bristol-Myers Squibb has announced strong third quarter results with sales up 9% to $4.1 billion.

BaracludeBristol-Myers SquibbFinancialNorth AmericaOnglyzaOrenciaPharmaceuticalSprycelYervoy

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

New EULAR recommendations address use of synthetic and biological DMARDs

05-07-2013

The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China

14-06-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

1 to 9 of 69 results

COMPANY SPOTLIGHT

Menarini

Back to top